The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer


Published in:
Human Pathology

DOI:
10.1016/j.humpath.2010.04.017

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2010

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Original contribution

The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer

Jasper J. H. Eijsink MD\textsuperscript{a}, Maartje G. Noordhuis\textsuperscript{a}, Klaske A. ten Hoor\textsuperscript{a}, Mirjam Kok\textsuperscript{a}, Harry Hollema MD, PhD\textsuperscript{b}, Geertruida H. de Bock PhD\textsuperscript{c}, Hans W. Nijman MD, PhD\textsuperscript{a}, Ed Schuuring PhD\textsuperscript{b}, G. Bea A. Wisman PhD\textsuperscript{a}, Ate G. J. van der Zee MD, PhD\textsuperscript{a,\textsuperscript{*}}

\textsuperscript{a}Department of Gynaecologic Oncology, University Medical Center Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands
\textsuperscript{b}Department of Pathology, University Medical Center Groningen, University of Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands
\textsuperscript{c}Department of Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands

Received 16 December 2009; revised 6 April 2010; accepted 8 April 2010

Keywords: Cervical cancer; EGFR pathway; Survival; Metastasis

Summary The objective of this study is to correlate the expression of epidermal growth factor receptor (EGFR) components with clinical behavior of early-stage cervical cancer. Tissue samples of 336 consecutive Federation of International Gynecologists and Obstetricians stage IB-IIA cervical cancer patients all treated primarily by radical surgery were collected. Clinicopathologic and follow-up data were prospectively obtained during standard treatment and follow-up. As representatives for the EGFR pathway, expression of EGFR, pEGFR, PTEN, pAKT, and pERK was assessed by immunohistochemistry on tissue microarrays. Positive immunostaining was observed for EGFR in 32.1\%, for pEGFR in 21.0\%, for PTEN in 38.3\%, for pAKT in 5.3\%, and for pERK in 4.3\% of tumor samples. Positive EGFR immunostaining was associated with squamous cell carcinoma of the cervix (odds ratio [OR], 7.41; 95\% confidence interval [CI], 3.38-16.23, \textit{P} < .001), negative pEGFR immunostaining with poor differentiation (OR, 0.39; 95\% CI, 0.20-0.73, \textit{P} = .004), and negative PTEN immunostaining with metastatic pelvic lymph nodes (OR, 0.51; 95\% CI, 0.30-0.90, \textit{P} = .019). In multivariate analysis, only pelvic lymph node metastasis (hazard ratio, 6.11; 95\% CI, 3.46-10.77, \textit{P} < .001) and poor differentiation (hazard ratio, 1.91; 95\% CI, 1.12-3.26, \textit{P} = .018) were related to disease-specific survival. In early-stage cervical cancer, loss of PTEN expression is associated with pelvic lymph node metastasis, suggesting PTEN to be one of the tumor suppressor genes affecting pelvic lymph node metastasis. However, expression of EGFR pathway components does not appear to have prognostic impact in surgically treated early-stage cervical cancer.

© 2010 Elsevier Inc. All rights reserved.

* Corresponding author.
E-mail address: a.g.j.van.der.zee@og.umcg.nl (A. G. J. van der Zee).
1. Introduction

Early-stage cervical cancer is generally treated by radical hysterectomy and pelvic lymph node dissection. In cases with poor clinicopathologic factors, adjuvant radiotherapy with or without chemotherapy is often administered. Conventional prognostic factors in early-stage cervical cancer are tumor size, depth of stromal invasion, lympho-vascular space involvement, parametrial invasion, and pelvic lymph node metastasis [1-4]. Pelvic lymph node metastasis appears to be the most important of these parameters [5], with a 5-year survival approximating 90% in node-negative early-stage cervical cancer patients primarily treated with surgery and decreasing to approximately 65% in patients with pelvic lymph node metastasis [6]. In early-stage cervical cancer, molecular markers could be helpful in selecting lymph node–negative patients with an unfavorable prognosis for adjuvant treatment and might identify new targets for patient-tailored therapy.

The epidermal growth factor receptor (EGFR) is involved in the ErbB signaling network, which is often deregulated in cancer. Autophosphorylation of EGFR to pEGFR leads to activation of the Ras/Raf/MEK/ERK pathway and the phosphoinositide 3-kinase (PI3K)/AKT pathway, both of which are involved in processes that are associated with carcinogenesis and tumor progression, such as inhibition of apoptosis, cell migration, cell growth, and angiogenesis [7]. PTEN (phosphatase and tensin homolog deleted on chromosome 10) acts as a tumor suppressor gene by inhibiting phosphorylation and thereby activation of AKT [8,9]. Only few data, obtained in small series of cervical cancer patients primarily treated by surgery, exist on EGFR or PTEN expression [10-13], and no published studies provide a comprehensive analysis of several EGFR pathway components simultaneously in a well-defined series of early-stage cervical cancer patients.

Previous studies of molecular markers in early-stage cervical cancer have been limited by the small number of patients evaluated and/or mediocre documentation of clinicopathologic parameters. The present study was designed to correlate expression of EGFR, pEGFR, PTEN, pAKT, and pERK in relation to clinicopathologic parameters and disease-specific survival in a large, well-documented series of patients with early-stage cervical cancer and long-term follow-up.

2. Materials and methods

2.1. Patients and treatment

Since 1980, clinicopathologic characteristics and follow-up data of all cervical cancer patients referred to the Department of Gynaecologic Oncology of the University Medical Center Groningen, the Netherlands, have been prospectively entered into a computerized database. Clinical staging of each patient is performed under general anesthesia in accordance with the Federation of International Gynecologists and Obstetricians (FIGO) criteria. For the present study, we selected all early-stage cervical cancer patients, treated primarily by surgery between January 1980 and December 2004 from our database (n = 336). All patients underwent type 3 radical hysterectomy and pelvic lymph node dissection. Patients with pelvic lymph node metastases, parametrial invasion, or positive excision margins received adjuvant external beam radiotherapy with or without chemotherapy. Paraffin-embedded formalin-fixed primary tumor tissue was collected from each patient. Patients were only included in our analysis if sufficient representative tumor tissue was available for tissue microarray (TMA) construction. After completion of treatment, patients were followed up at the outpatient clinic for at least 5 years.

2.2. Institutional review board approval

In the University Medical Center Groningen, clinicopathologic and follow-up data are prospectively obtained during standard treatment and follow-up and stored in a computerized registration database. For the present study, all relevant data were retrieved from this computerized database into a separate, anonymous database. Patient identity was protected by study-specific, unique patient numbers. Codes were only known to 2 dedicated data managers, who also have daily responsibility for the larger database. In case of uncertainties with respect to clinicopathologic and follow-up data, the larger databases could only be checked through the data managers, thereby ascertaining the protection of patients’ identity. Using the registration database, we identified all tissue specimens by unique patient numbers and retrieved them from the archives of the Department of Pathology. Therefore, according to Dutch law, no further Institutional Review Board approval was needed for this study (http://www.federa.org/).

2.3. Tissue microarray construction

As previously described, representative areas of tumor were marked on hematoxylin and eosin–stained slides of the paraffin-embedded tissue [14]. Areas of necrosis and/or heavy leukocytic infiltrate were avoided. The TMAs were constructed using a precision instrument (Beecher Instruments, Silver Spring, MD). Three 0.6 mm in diameter cores were punched from the marked area of the paraffin-embedded tissue (donor block) and transferred to a predefined location in a blank paraffin block (recipient block). After all the cores had been inserted, the recipient block was placed in an oven of 37°C for 15 minutes to attach the cores to the surrounding paraffin. Each TMA also contained benign (skin epithelia, normal cervical tissue, and colon polyps) and tumor (breast, colon and ovarian carcinoma) tissue that served as controls.
for immunostaining and comparison of TMAs. In total, 5 TMAs were constructed.

### 2.4. Immunohistochemistry

For immunohistochemistry, 4-μm sections were cut from the TMA and mounted on amino-propyl-ethoxy-silan (Sigma-Aldrich, Diessenhofen, Germany)-coated glass slides. Immunohistochemistry for EGFR, pEGFR, PTEN, pAKT, and pERK was performed as described previously [15]. Details of the antibodies used for immunohistochemistry and methods for antigen retrieval are summarized in Table 1. The avidin-biotin-peroxidase method was used for all antibody detection, except pAKT for which the EnVision horseradish peroxidase system (Dako, Copenhagen, Denmark) was used. Slides were deparaffinized in xylene and rehydrated in ethanol. Endogenous peroxidase was blocked by incubation with 0.3% hydrogen peroxide for 30 minutes. For staining in which the avidin-biotin-peroxidase method was used, endogenous avidin and biotin activity was blocked using a blocking kit (Vector Laboratories, Burlingame, UK). Immunostaining was visualized by 3′-3-diaminobenzidine tetrahydrochloride, and counter immunostaining was performed with hematoxylin.

### 2.5. Evaluation of immunostaining

Scoring was performed by 2 independent observers (JJHE and MGN) without knowledge of clinical data. A concordance of more than 90% was found. The discordant cases were reviewed, and scores were reassigned on consensus. Immunostaining intensity was semiquantitatively scored. Only patients with at least 2 representative cores were included in the analysis. Tumors were considered positive for EGFR when more than 10% positive membranous immunostaining was observed [12]. pAKT and pERK immunostaining were considered positive if more than 10% of a tumor showed cytoplasmic and/or nuclear immunostaining [15]. Positive expression of PTEN was defined as more than 10% cytoplasmic immunostaining [16]. Positive pEGFR was defined as at least weak positive cytoplasmic immunostaining, as the activated EGFR is internalized [17].

### 2.6. Statistical analysis

Statistical analysis was performed with SPSS 16.0 for Windows (SPSS Inc, Chicago, IL). Associations (odds ratios [ORs] and 95% confidence interval [CI]) between immunostaining intensity and clinicopathologic characteristics were assessed in a univariate logistic regression model using positive protein expression as dependent factor and the clinicopathologic characteristics as independent factors. Relations (hazard ratios [HR] and 95% CI) between disease-specific survival, clinicopathologic features, and immunostaining were calculated using both univariate and multivariate Cox proportional hazard analysis. In these analyses, factors with a P value greater than .10 in the univariate analyses were excluded stepwise in multivariate analyses. P values of less than .05 were considered statistically significant.

### 3. Results

#### 3.1. Patients and tumor characteristics

In total, 336 patients diagnosed with early-stage cervical cancer (IB1: n = 221 [66%]; IB2: n = 63 [19%]; IIA: n = 52 [15%]) and treated by radical hysterectomy and pelvic lymph node dissection were identified. In 310 cases, sufficient pretreatment tissue was available for TMA construction. Median age was 43 years (range, 17-86 years), and median follow-up time was 5.5 years (range, 0.31-18.60 years). Overall, 5-year disease-specific survival for the 310 patients was 82.4%. Additional patient and tumor characteristics are summarized in Table 2.

#### 3.2. Clinicopathologic factors in relation to EGFR, pEGFR, PTEN, pAKT, and pERK

The proportion of patients included in the analysis based on 2 or more representative cores was 93.5% for EGFR, 93.5% for pEGFR, 91.0% for PTEN, 90.7% for pAKT, and 89.1% for pERK. Fig. 1 shows a representative negative and

### Table 1 Antibodies used for immunostaining

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Antigen retrieval</th>
<th>Clone</th>
<th>Company</th>
<th>Dilution</th>
<th>Incubation time</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTEN</td>
<td>Citrate (pH 6)</td>
<td>6H2.1</td>
<td>Cascade</td>
<td>1:100</td>
<td>60 min</td>
</tr>
<tr>
<td>EGFR</td>
<td>Protease K 0.1%, 30 min</td>
<td>111.6</td>
<td>Neomarkers</td>
<td>1:200</td>
<td>60 min</td>
</tr>
<tr>
<td>pEGFR</td>
<td>EDTA (pH 8)</td>
<td>1H12</td>
<td>Cell Signaling</td>
<td>1:200</td>
<td>60 min</td>
</tr>
<tr>
<td>pAKT 1/2</td>
<td>Citrate (pH 6)</td>
<td>736E11</td>
<td>Cell Signaling</td>
<td>1:50</td>
<td>Overnight (4°C)</td>
</tr>
<tr>
<td>pERK 1/2</td>
<td>Citrate (pH 6)</td>
<td>20G11</td>
<td>Cell Signaling</td>
<td>1:50</td>
<td>Overnight (4°C)</td>
</tr>
</tbody>
</table>

* Sections were boiled in a microwave for 15 minutes.

* Cascade Bioscience, Winchester, MA.

* Neomarkers, Lab Vision Corporation, Fremont, CA.

* Cell Signaling, Danvers, MA.
positive core for each staining. Positive EGFR immunostaining was observed in 93 (32.1%) of 290 patients, positive pEGFR immunostaining in 61 of 290 (21.0%) patients, positive PTEN immunostaining in 108 (38.3%) of 282 patients, positive pAKT immunostaining in 15 (5.3%) of 281 patients, and positive pERK immunostaining in 12 (4.3%) of 276 patients. Positive pEGFR immunostaining correlated with PTEN (OR, 2.454; 95% CI, 1.367-4.403, \( P = .003 \)) and with pERK (OR, 4.468; 95% CI, 1.380-14.468, \( P = .013 \)). No additional correlations between the immunostains were found (data not shown).

Table 3 shows clinicopathologic features in relation to immunostaining. Positive membranous immunostaining for EGFR was associated with squamous cell carcinoma of the cervix (OR, 7.41; 95% CI, 3.38-16.23, \( P < .001 \)), negative pEGFR cytoplasmic immunostaining was associated with
poor differentiation (OR, 0.39; 95% CI, 0.20-0.73, \( P = .004 \)), and negative PTEN immunostaining was associated with metastatic pelvic lymph nodes (OR, 0.51; 95% CI, 0.30-0.90, \( P = .019 \)).

### 3.3. EGFR, pEGFR, PTEN, pAKT, and pERK and disease-specific survival

In univariate Cox regression analysis, none of the immunostain results correlated with disease-specific survival (Table 4). In multivariate Cox regression analysis, only positive lymph nodes (HR, 6.11; 95% CI, 3.46-10.77, \( P < .001 \)) and poor differentiation (HR, 1.91; 95% CI, 1.12-3.26, \( P = .018 \)) were independent prognostic factors for disease-specific survival.

### 4. Discussion

Immunohistochemical expression of EGFR pathway components EGFR, pEGFR, PTEN, pAKT, and pERK was evaluated in relation to clinicopathologic parameters and disease-specific survival in a consecutive series of early-stage cervical cancer patients. Our study indicates that loss of PTEN expression frequently occurs in early-stage cervical cancer and is related to pelvic lymph node metastasis (OR, 0.51; 95% CI, 0.30-0.90, \( P = .019 \)), but not to survival. Only limited data exist on PTEN expression and its possible implications for the biologic behavior of cervical cancer. In a study by Lee et al [13], reduced PTEN expression was identified in 17.6% (15/85) of surgically treated cervical cancer patients and was associated with decreased disease-free and overall survival, but not with pelvic lymph node metastasis. They reported a gradual reduction of PTEN expression along the continuum from normal epithelium through intraepithelial neoplasia to squamous cell carcinoma. Discrepancies between the data from Lee et al [13] and our study might be due to the number of evaluated patients (n = 85 vs n = 310) and/or interpretation of immunostaining, because Lee et al defined reduced PTEN expression by comparison with corresponding normal tissue. In our opinion, a minimal percentage of positive cells should be taken into account when assessing PTEN expression in a tumor. In a study comparing different immunostaining in TMA and full sections of vulvar cancer patients, a minimal percentage of positive cells was also taken into account, and this study resulted in a good reproducibility of immunostaining on TMA [18].

Experimental data also indicate a role for loss of PTEN in determining the metastatic potential of tumors. In a study using a benign melanocytic hyperplasia mice model, silencing PTEN leads to the development of melanoma and metastases to lymph nodes and lungs [19]. In a study of colorectal cancer patients, Sawai et al [20] observed an association between reduced PTEN expression and liver
metastases. Activation of receptor tyrosine kinases such as epidermal growth factor receptor, Her2/neu, and insulin-like growth factor receptor 1 results in recruitment of PI3K [9]. The direct product of PI3K is phosphatidylinositol-3,4,5-triphosphate (PIP3), and PIP3 is the primary target of PTEN [21]. Loss of PTEN function results in accumulation of PIP3 and thereby deletes activation of its downstream targets, the AKT pathway. Activation of the AKT pathway may cause cell cycle progression, cell survival, cell spreading and motility, and angiogenesis [9]. In our study, no relation between loss of PTEN and activation of the AKT pathway was found. Our low percentage (5.3%) of pAKT-positive cases is in contrast to previous studies in cervical cancer that used the same antibody and staining protocol but observed 29% to 94% pAKT-positive cases [22-24]. A major difference between these studies and our study is that we assessed pAKT in a much larger series (310 vs 31) of early-stage cervical cancer patients.

Loss of PTEN can be due to mutations, deletions, gene promoter methylation, or microRNAs (miRs) [25-28]. Mutations and deletions of PTEN are rare events in cervical cancer [16,22,29]. In a study by Yang et al, PTEN methylation was observed in 20 (15.7%) of 127 cervical cancers, whereas Cheung et al [16] reported PTEN methylation in 36 (58%) of 62 squamous cell cervical cancers. They found no PTEN expression in 3 of 10 PTEN methylation−negative cases and in 0 of 10 PTEN methylation−positive cases. Preliminary data from our cases show PTEN gene promoter methylation in 4 (21%) of 19 cases. No PTEN immunostaining was observed in these 4 PTEN methylation−positive cases (data not shown). Loss of PTEN expression could also occur via miRs. Several miRs, such as miR-21 and miR-214, can target PTEN [27,28]. Both miRs appear to be up-regulated in cervical cancer [30,31], but a relation with PTEN loss has not been reported. It might be that loss of PTEN expression can only partially be explained by down-regulation via miRs.

A downstream component of the PI3K/AKT pathway, known as the mammalian target of rapamycin (mTOR) pathway, is up-regulated in many cancers. As a consequence of PTEN loss, activation of the mTOR pathway may occur. As shown in vitro and in vivo experiments, cells without PTEN are more sensitive to mTOR inhibitors (rapamycin) [32,33]. These mTOR inhibitors might provide efficacious additional therapy in cervical cancer patients with an unfavorable prognosis and loss of PTEN.

Our study indicates a strong relation between squamous cell carcinomas and EGFR staining, which was previously reported in cervical cancer by Kersemaekers et al [11]. In their study, EGFR overexpression was observed in 54% (73/136) cervical cancer cases and was associated with reduced disease-free and overall survival in surgically treated cervical cancer patients [11]. These findings could not be confirmed in our large series of cervical cancer patients, where 32.1% of cases overexpressed EGFR. One explanation might be the use of a different antibody. Another possibility is that our study included a larger percentage of adenocarcinomas (28% vs 9%), and as is shown in our study, EGFR expression is highly associated with squamous cell carcinoma.

In conclusion, in early-stage cervical cancer, loss of PTEN expression is associated with pelvic lymph node metastasis, suggesting that PTEN is one of the tumor suppressor genes affecting pelvic lymph node metastasis in early-stage cervical cancer. Overall, however, the EGFR pathway does not appear to have prognostic impact in surgically treated early-stage cervical cancer.

References


| Table 4 Disease-specific survival (Cox regression analysis) |
|-----------------|-----------------|-----------------|
|                | Univariate       | Multivariate    |
|                | HR (95% CI)      | HR (95% CI)     |
| Age            | 1.02 (1.00-1.04) | 1.19 (1.12-3.26) |
| Stage ≥IB2     | 2.34 (1.38-3.98) | 1.91 (1.12-3.26) |
| Squamous       | 0.72 (0.40-1.29) | 1.59 (0.92-2.75) |
| Poor differentiation | 1.73 (1.01-2.95) | 1.91 (1.12-3.26) |
| Lymphangioinvasion | 2.38 (1.32-4.26) | 1.91 (1.12-3.26) |
| Infiltration depth ≥10 mm | 2.00 (1.15-3.49) | 1.91 (1.12-3.26) |
| Positive lymph nodes | 5.76 (3.30-10.04) | 1.91 (1.12-3.26) |
| Tumor diameter ≥4 cm | 2.45 (1.44-4.16) | 1.91 (1.12-3.26) |
| EGFR           | 1.24 (0.69-2.22) | 1.91 (1.12-3.26) |
| pEGFR          | 0.81 (0.39-1.66) | 1.91 (1.12-3.26) |
| PTEN           | 0.61 (0.33-1.14) | 1.91 (1.12-3.26) |
| pAKT           | 0.71 (0.17-2.93) | 1.91 (1.12-3.26) |
| pERK           | 0.05 (0.00-15.02)| 1.91 (1.12-3.26) |

Abbreviation: # = not included in final analysis.
Expression of EGFR components in early-stage cervical cancer


